The RABIOPRED consortium is coordinated by Tc Land Expression S.A., a French SME developing biomarkers for personalized medicine and companion diagnostics in immune mediated disorders. For more information on Tc Land, please visit
Firalis S.A.S. is a project partner and the parent company of Tc Land. Firalis is a leader SME in biomarker R&D, developing innovative diagnostic solutions in particular for cardiovascular desease and toxicities. For more information on Firalis, please visit www.firalis.com
The Project has officialy started on the 01 July 2015 and is funded fully for all costs to be generated within 42 months of its duration.
RABIOPRED Consortium will realize a "Prospective observational multicenter confirmatory Proof-of-Performance (PoP) clinical trial", within years 2 and 3 of the project, in participation of 5 highly prestigious clinical research centers:
More information on these clinical centers will be available soon on this page. Until then, do not hesitate to contact us for your questions.